biote Corp. (BTMD) Revenue History
Annual and quarterly revenue from 2019 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
BTMD Revenue Growth
Revenue Breakdown (FY 2025)
BTMD's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
BTMD Revenue Analysis (2019–2025)
As of May 8, 2026, biote Corp. (BTMD) generated trailing twelve-month (TTM) revenue of $188.2 million, reflecting moderate decline in growth of -8.3% year-over-year. The most recent quarter (Q1 2026) recorded $44.9 million in revenue, down 3.2% sequentially.
Looking at the longer-term picture, BTMD's 5-year compound annual growth rate (CAGR) stands at +10.5%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $197.2 million in 2024.
Revenue diversification analysis shows BTMD's business is primarily driven by Product Revenue (78%), Dietary Supplements (18%), and Service Revenue (2%). With over half of revenue concentrated in Product Revenue, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including HIMS (+59.0% YoY), EVAX (+125.8% YoY), and AMWL (-30.3% YoY), BTMD has underperformed the peer group in terms of revenue growth. Compare BTMD vs HIMS →
BTMD Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| BTMDCurrent | $188M | -8.3% | +10.5% | 18.5% | |
 HIMS | $2.3B | +59.0% | +73.6% | 5.2% | |
 EVAX | $8M | +125.8% | - | -122.7% | |
 AMWL | $249M | -30.3% | +0.3% | -42.2% | |
 NUVB | $63M | +1205.5% | - | -338.7% | |
 GDRX | $797M | -1.2% | +7.7% | 13.4% |
BTMD Historical Revenue Data (2019–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $192.2M | -2.5% | $137.4M | 71.5% | $35.6M | 18.5% |
| 2024 | $197.2M | +6.4% | $139.1M | 70.5% | $31.6M | 16.0% |
| 2023 | $185.4M | +12.4% | $127.5M | 68.8% | $28.7M | 15.5% |
| 2022 | $165.0M | +18.3% | $110.4M | 66.9% | $-60,722,000 | -36.8% |
| 2021 | $139.4M | +19.6% | $90.6M | 65.0% | $34.6M | 24.8% |
| 2020 | $116.6M | +6.0% | $71.6M | 61.5% | $31.8M | 27.3% |
| 2019 | $110.0M | - | $66.4M | 60.4% | $23.5M | 21.4% |
See BTMD's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BTMD Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BTMD vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBTMD — Frequently Asked Questions
Quick answers to the most common questions about buying BTMD stock.
Is BTMD's revenue growth accelerating or slowing?
BTMD revenue declined -8.3% year-over-year, contrasting with the 5-year CAGR of +10.5%. TTM revenue fell to $188M. This reverses the prior growth trend.
What is BTMD's long-term revenue growth rate?
biote Corp.'s 5-year revenue CAGR of +10.5% reflects the variable expansion pattern. Current YoY growth of -8.3% is below this long-term average.
How is BTMD's revenue distributed by segment?
BTMD reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2019-2025 are available for download. Segment mix reveals concentration and diversification trends.